Tech Company Financing Transactions
Velicept Therapeutics Funding Round
On 10/17/2018, Velicept Therapeutics raised $15 million in Series B funding from Samsara BioCapital, Becker Ventures and CDK Ventures.
Transaction Overview
Company Name
Announced On
10/17/2018
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
This financing provides us the capital necessary to complete the robust Phase 2 program and ready the program to enter Phase 3.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
640 Lee Rd. 119
Wayne, PA 19087
USA
Wayne, PA 19087
USA
Phone
Website
Email Address
Not Recorded
Overview
Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Walker
Chief Financial Officer
Douglas Gessl
Chief Medical Officer
Clarence Young
Chief Scientific Officer
Eliot Ohlstein
VP - Operations
Ray Stevens
Browse more venture capital transactions:
Prev: 10/17/2018: Hubb venture capital transaction
Next: 10/17/2018: Paperspace venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs